Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer

Yosuke Yasuda; Soichiro Yoshida; Sadakatsu Ikeda; Ichiro Yonese; YUTA SANO; Tetsuya Urasaki; Yuki Nakamura; Hajime Tanaka; M. Ito; Y. Miura; Noboru Numao; Yoh Matsuoka; F. Koga; J. Yonese; Yasuhisa Fujii

doi:10.1093/jjco/hyag039

February 23, 2026Japanese Journal of Clinical Oncology

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

To explore the role of genomic profiling in guiding treatment decisions for metastatic castration-resistant prostate cancer.
Comprehensive genomic profiling (CGP) was performed on patients with metastatic castration-resistant prostate cancer (CRPC).
The study assessed the identification of specific genomic alterations and their correlation with therapy outcomes.
Data analysis focused on the prevalence of BRCA pathogenic variants, MSI-high, and TMB-high status.
20% of patients with metastatic CRPC had BRCA pathogenic variants, MSI-high, or TMB-high.
Only a subset of identified patients received matched therapeutic interventions.
The findings support earlier implementation of CGP in treatment planning.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

CGP identifies targets in metastatic castration-resistant prostate cancer, highlighting opportunities for precision oncology treatment.

Abstract

CGP identified BRCA PVs, MSI-high, or TMB-high in 20% of patients with metastatic CRPC, supporting its value in guiding precision oncology. However, only some patients received matched therapy, supporting earlier CGP testing. Routine integration of CGP may facilitate precision oncology-guided treatment decision-making in this population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yasuda et al. (2026) studied this question.

synapsesocial.com/papers/69b5ff6e83145bc643d1bf7f https://doi.org/10.1093/jjco/hyag039

View at Publisher

Ask AI

Bookmark

Share

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading